Compare Extra Space Storage, Inc. (EXR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Sanofi SA — how do they compare? Extra Space Storage, Inc. trades at $147.22 (market cap $30.96B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3.4× Extra Space Storage, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| EXR | SNY | |
|---|---|---|
Market Cap | $30.96B | $104.30B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $52.34 |
52-Week Low | $126.67 | $41.33 |
Enterprise Value | $44.68B | $124.19B |
Dividend Yield | 4.42% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $147.22, up 0.38% today, near its 52-week high with a consensus price target of $157.25. The stock shows strong fundamentals, with Q2 2026 EPS beating estimates and a dividend yield supported by robust cash flow. Technicals are bearish on moving averages but neutral on oscillators, with key resistance at $148. Revenue growth has been steady, and the company maintains high profitability margins.
Outlook is positive with consistent earnings beats and a solid balance sheet, though high valuation multiples and competitive pressures pose risks. Analysts are mixed with a 'Hold' consensus, but institutional interest remains strong. The stock offers growth potential but requires monitoring of debt levels and market sentiment shifts.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
